News | June 05, 2013

Loma Linda Proton Treatment Center Announces Multiple Clinical Trials Open to Patients

June 5, 2013 — Loma Linda University Medical Center (LLUMC) currently has openings in eight clinical trials for patients with certain types of cancers of the breast, prostate, liver, esophagus and pancreas as well as those with soft-tissue sarcoma. All of the trials involve the use of proton therapy and are approved by the Institutional Review Board, the independent national committee that oversees such trials.

The use of proton beam radiation as a cancer treatment was developed and brought to use by scientists at LLUMC more than 20 years ago. Since that time Loma Linda’s Proton Treatment and Research Center has cared for more than 15,000 cancer patients, making it the most dynamic proton treatment center in the world.

“The ongoing study of proton therapy helps to enhance patient care and furthers the technology as the premiere radiation treatment modality for cancer and other diseases,” said Jerry D. Slater, M.D., chairman of the LLUMC Proton Treatment and Research Center. “Our clinical research studies provide us with the platforms to improve existing cancer treatment protocols and develop new protocols to treat other diseases.”

The proton beam’s structure makes it the most precise form of radiation. Its pinpoint accuracy allows proton beams to target a specific area while sparing surrounding healthy tissue. “We are continually looking at increasing proton treatment’s safety and reducing its side effects in comparison to other forms of radiation therapy, with the ultimate goal to improve and streamline treatment strategies,” Slater said.

Current trials to which qualified patients can join include:

  • Breast Cancer — Building upon an earlier successful breast cancer trial, this study looks at patients with slightly higher risk factors to determine if the same excellent results in disease control and freedom from side effects can be achieved. Principal investigator: David A. Bush, M.D. For more information:
  • Esophageal Cancer — This trial studies whether a combination of chemotherapy can work with a low proton dose to control disease and prolong survival. Principal investigator: Gary Yang, M.D. For more information:
  • Liver Cancer — Proton treatment at LLUMC is effective in reducing tumors in liver cancers that meet Milan and San Francisco criteria. Currently TACE is a standard treatment for these patients. This study compares proton therapy outcomes with results in patients treated with TACE with the hopes of potentially improving overall treatment outcomes. Principal investigators: David A. Bush, M.D., and Michael De Vera, M.D. For more information:
  • Liver Cancer — Sorafenib is a standard chemotherapy for treating patients with advanced liver cancers. This study will determine if adding proton therapy to that chemotherapy can significantly reduce tumors. Principal investigators: David A. Bush, M.D., and Michael De Vera, M.D. For more information:
  • Liver Cancer — For tumors that have metastasized to the liver and cannot be treated with surgery, aggressive radiotherapy can also prolong survival. Proton therapy can potentially improve clinical outcomes with less morbidity. This trial studies the feasibility and safety of using protons for isolated liver metastases. Principal investigator: Gary Yang, M.D. For more information:
  • Pancreatic Cancer — Pancreatic cancer when diagnosed typically is advanced making chemotherapy and conventional radiation more difficult to use. This study will research whether a limited proton dose can reduce tumors, minimize side effects, and make chemotherapy more effective. Principal investigator: Gary Yang, M.D. For more information:
  • Prostate Cancer — Proton treatments at LLUMC have long been successful controlling disease and reducing side effects for prostate cancer patients. This study looks at shortening treatment time in half from eight to four weeks. Principal investigator: Jerry D. Slater, M.D. For more information:
  • Soft Tissue Sarcoma — Surgery is the preferred method of controlling soft-tissue sarcomas, and standard radiation may be used to reduce tumors so surgery is more effective. However, radiation-injured normal tissue can compromise surgery. This trial will look at whether proton therapy, by sparing more normal tissue, can increase surgery’s effectiveness. Principal investigator: Gary Yang, M.D. For more information:


For more information:

Related Content

Doctor-Patient Discussions Neglect Potential Harms of Lung Cancer Screening
News | Lung Cancer | August 15, 2018
August 15, 2018 — Although national guidelines advise doctors to discuss the benefits and harms of...
Videos | Proton Therapy | August 10, 2018
A discussion with Matthew Freeman, Ph.D., scientist at Los Alamos National Laboratory, New Mexico.
Cardiac Imaging Reveals Roots of Preeclampsia Damage in Pregnant Women
News | Women's Health | August 07, 2018
Johns Hopkins researchers say a heart imaging study of scores of pregnant women with the most severe and dangerous form...
Cardiac Monitoring a Higher Priority for High-Risk Breast Cancer Patients
News | Cardio-oncology | August 07, 2018
August 7, 2018 — While heart failure is an uncommon complication of...
IBA Completes Installation of Two Proteus One Proton Therapy Systems in Japan
News | Proton Therapy | July 30, 2018
IBA (Ion Beam Applications S.A.) announced that they completed the first two installations of the Proteus One proton...
computed tomography brain scan

Image courtesy of Pixabay

News | Clinical Trials | July 19, 2018
The use of computed tomography (CT) scans has increased dramatically over the last two decades. CT scans greatly...
CT Decision Instrument Reliably Guides Pediatric Blunt Trauma imaging Decisions

This is a four-site prospective observational cohort. Image courtesy of Kirsty Challen, B.Sc., MBCHB, MRES, Ph.D., Lancashire Teaching Hospitals, United Kingdom.

News | Clinical Decision Support | July 18, 2018
A new study finds The Pediatric NEXUS Head Computed Tomography (CT) Decision Instrument (DI) reliably identifies blunt...
Study Points to Need for Performance Standards for EHR Usability and Safety
News | Electronic Medical Records (EMR) | July 18, 2018
A novel new study provides compelling evidence that the design, development and implementation of electronic health...
Artificial Intelligence Provides Faster, Clearer MRI Scans

A new artificial-intelligence-based approach to image reconstruction, called AUTOMAP, yields higher quality images from less data, reducing radiation doses for CT and PET and shortening scan times for MRI. Shown here are MR images reconstructed from the same data with conventional approaches, at left, and AUTOMAP, at right. Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital

News | Artificial Intelligence | July 17, 2018
A research team with funding from the National Institute for Biomedical Imaging and Bioengineering (NIBIB) has...
Study Shows Biomarker Panel Boosts Lung Cancer Risk Assessment for Smokers
News | Lung Cancer | July 16, 2018
A four-protein biomarker blood test improves lung cancer risk assessment over existing guidelines that rely solely upon...
Overlay Init